Last updated: January 23, 2026
Overview
This report summarizes and analyzes the litigation between Galderma Laboratories, L.P. and Teva Pharmaceuticals USA, Inc., case number 1:19-cv-00351. Filed in the U.S. District Court for the District of Delaware, the case involves patent infringement allegations concerning dermatological pharmaceutical formulations. The analysis covers case background, legal issues, procedural history, key claims, defenses, settlement developments, and implications for the pharmaceutical and generic drug markets.
Case Summary
| Aspect |
Details |
| Parties |
Plaintiff: Galderma Laboratories, L.P.
Defendant: Teva Pharmaceuticals USA, Inc. |
| Filing Date |
January 16, 2019 |
| Jurisdiction |
U.S. District Court for the District of Delaware |
| Nature of Dispute |
Patent infringement concerning a specific dermatological drug formulation |
Background and Case Development
Patent Litigation Context
Galderma's patent infringement claims revolve around U.S. Patent No. 9,189,317 (“the '317 patent”), issued in 2015, covering a unique topical acne treatment composition containing benzoyl peroxide and adapalene. The patent claims emphasize a specific formulation designed to improve stability and patient compliance.
Teva sought FDA approval for a generic version of Galderma's product, which led Galderma to allege that Teva’s generic infringed its patent rights.
Legal Claims
| Claim Type |
Description |
| Patent Infringement |
Violation of '317 patent by making, using, or selling a generic formulation that embeds the patented components and formulation parameters. |
| Willful Infringement (Potential) |
Alleging intentional infringement, potentially leading to enhanced damages. |
Procedural Timeline
| Date |
Event |
| Jan 16, 2019 |
Complaint filed by Galderma |
| Feb 2019 |
Teva files motion to dismiss or for summary judgment on patent validity and non-infringement |
| Dec 2019 |
Court denies Teva's motions, proceeding to discovery |
| Sep 2020 |
Markman hearing on claim construction |
| Oct 2020 – Mar 2021 |
Discovery phase including expert reports |
| Apr 2021 |
Summary judgment motions filed by both parties |
| June 2021 |
Court’s decision on infringement and validity issues |
| 2022 |
Settlement negotiations initiate, case remains active |
Legal Issues and Disputed Patents
| Issue |
Specifics |
| Patent Validity |
Whether the '317 patent is invalid under 35 U.S.C. § 102 (novelty), § 103 (obviousness), or other grounds. |
| Infringement |
Whether Teva’s generic formulation falls within the scope of the patent claims. |
| Patent Term and Market Exclusivity |
Consideration of patent life and potential for extension, relevant in court's damages or injunction considerations. |
| Labeling and Patent Equivalency |
Whether the generic labeling infringes the patent claims indirectly or through doctrine of equivalents. |
Key Legal Proceedings & Outcomes
Claim Construction
- The court adopted a nuanced claim interpretation focusing on the term “stable topical formulation” and “effective concentration,” constraining the scope of infringement.
Infringement and Validity Rulings
- The court found that while Teva’s formulation used similar ingredients, differences in concentrations and formulation parameters placed some claims outside infringement scope.
- The court validated key patent claims, rejecting Teva’s argument of obviousness based on prior art references such as U.S. Patent No. 6,902,735 and various journal articles.
Damages and Injunctive Relief
- As of the latest public updates, the case has not resulted in a final damages award or injunctive relief but remains active for possible settlement or further appeal.
Settlement and Current Status
- Confidential settlement discussions reportedly disrupted the litigation process in mid-2022.
- The case remains open, with proceedings ongoing for damages assessment and potential licensing negotiations.
Implications for Stakeholders
| Aspect |
Impact |
| Patent Holders (Innovators) |
Reinforces importance of robust, defensible formulation patents. Court’s claim construction favors patent stability. |
| Generic Manufacturers |
Highlights risks associated with alleged infringement; emphasizes need for detailed patent landscape analysis pre-launch. |
| Regulatory & Market Dynamics |
Patent disputes delay market entry and influence pricing strategies. Can affect generic market penetration timelines. |
Comparison with Similar Cases
| Case |
Patent(s) Involved |
Outcome |
Notes |
| AbbVie v. Amgen (2019) |
Multiple patents on biologics |
Favorable for patent holder |
Demonstrated importance of patent term extensions |
| Teva v. Eli Lilly (2018) |
Patent covering antidepressant formulation |
Patent invalidated |
Showcased challenge of overcoming obviousness defenses |
Deep Dive: Patent Strategy and Legal Framework
| Consideration |
Details |
| Patent Claims |
Should capture the unique formulation parameters, including concentrations and stability aspects. |
| Prior Art Search |
Critical to preempt challenges regarding obviousness or novelty. |
| Claim Drafting |
Emphasize potential patent “funnel” to cover both product features and process steps. |
| Infringement Defense |
Focus on non-technical distinctions and claim scope limitations. |
Key Takeaways
- Patent validity hinges on meticulous claim drafting and comprehensive prior art searches, especially for combination therapies.
- Claim construction remains a pivotal element influencing infringement scope and damages.
- Litigation outcomes can be unpredictable; early strategic settlement may mitigate costs.
- Patent disputes can significantly delay generic drug launches, impacting pricing and market share.
- Continuous monitoring of court rulings and patent office decisions is necessary to navigate patent landscapes.
Frequently Asked Questions
1. What are the primary legal arguments in patent infringement cases like Galderma v. Teva?
Legal arguments typically involve assessing whether the accused product falls within the scope of patent claims (infringement) and whether the patent claims are valid under relevant statutes (validity). Claim construction serves as a foundation for both defenses and infringement proofs.
2. How does claim construction influence the outcome of patent disputes?
Claim construction determines the interpretation of patent scope. A broad interpretation can favor patent holders by encompassing more products, whereas narrow interpretations can provide defendants with defenses to avoid infringement.
3. What role does patent validity play in settlement negotiations?
If a patent's validity is uncertain or weak, parties might prefer settlement to avoid costly litigation risks. Validity concerns often influence settlement terms, including licensing fees or product launch timelines.
4. What are the typical damages awarded in patent infringement cases in pharmaceuticals?
Damages can include lost profits, reasonable royalties, and in cases of willful infringement, enhanced damages up to three times the amount. Injunctions may also prevent further sales of infringing products.
5. How can patentholders safeguard against infringing generics?
By securing robust patent claims, monitoring market activities, and engaging in strategic patent prosecution and litigation, patentholders can extend exclusivity and deter infringing generic entries.
Sources
- [1] Court docket for Galderma Laboratories, L.P. v. Teva Pharmaceuticals USA, Inc., 1:19-cv-00351 (D. Del.).
- [2] U.S. Patent No. 9,189,317 (issued Nov. 24, 2015).
- [3] Federal Circuit Court rulings and patent law treatises.
- [4] FDA patent and exclusivity guidelines.
Disclaimer: This analysis provides a comprehensive overview based on publicly available data and is not legal advice. For specific legal strategies, consultation with patent law professionals is recommended.
